Biologics CDMO Market Size, Share, Trends & Growth Opportunities Forecast to 2026 - 2035 - Table of Contents
1. Introduction
- 1.1 Market Definition and Scope
- 1.2 Research Methodology
- 1.3 Data Sources and Assumptions
- 1.4 Abbreviations
2. Executive Summary
- 2.1 Biologics CDMO Market Snapshot, 2025 and 2035
- 2.2 Key Findings
- 2.3 Analyst Recommendations
3. Market Overview
- 3.1 Biologics Outsourcing Value Chain
- 3.2 Global Biomanufacturing Capacity Analysis
- 3.3 Pricing and Contract Models
- 3.4 Regulatory Landscape and BIOSECURE Act
- 3.5 Technology Trends: Single-Use, Continuous and Perfusion
- 3.6 Porter’s Five Forces Analysis
4. Market Dynamics
- 4.1 Drivers
- 4.2 Restraints
- 4.3 Opportunities
- 4.4 Challenges
- 4.5 Key Trends, 2026
5. Biologics CDMO Market, By Service Type, 2021–2035 (USD Billion)
- 5.1 Drug Substance Manufacturing
- 5.2 Drug Product / Fill-Finish
- 5.3 Process Development
- 5.4 Analytical, QC & Other
- 5.5 Cell Line Development
6. Biologics CDMO Market, By Molecule Type, 2021–2035 (USD Billion)
- 6.1 Monoclonal Antibodies (incl. Bispecifics)
- 6.2 Recombinant Proteins & Enzymes
- 6.3 ADCs & Bioconjugates
- 6.4 Vaccines
- 6.5 Cell & Gene Therapies
- 6.6 mRNA & Others
7. Biologics CDMO Market, By Expression System, 2021–2035 (USD Billion)
- 7.1 Mammalian
- 7.2 Microbial
- 7.3 Others
8. Biologics CDMO Market, By Manufacturing Technology, 2021–2035 (USD Billion)
- 8.1 Stainless-Steel
- 8.2 Single-Use
9. Biologics CDMO Market, By Development Stage, 2021–2035 (USD Billion)
- 9.1 Commercial
- 9.2 Clinical
10. Biologics CDMO Market, By Biologic Type, 2021–2035 (USD Billion)
- 10.1 Innovator Biologics
- 10.2 Biosimilars
11. Biologics CDMO Market, By Therapeutic Application, 2021–2035 (USD Billion)
- 11.1 Oncology
- 11.2 Immunology & Inflammation
- 11.3 Infectious Diseases
- 11.4 Metabolic & Endocrine
- 11.5 Neurology
- 11.6 Hematology & Others
12. Biologics CDMO Market, By End User, 2021–2035 (USD Billion)
- 12.1 Large Pharmaceutical Companies
- 12.2 Small & Emerging Biotech
- 12.3 Mid-Size Pharma
- 12.4 Academic & Government Institutes
13. North America Biologics CDMO Market, 2021–2035 (USD Billion)
- 13.1 Market by Segment
- 13.2 U.S.
- 13.3 Canada
14. Europe Biologics CDMO Market, 2021–2035 (USD Billion)
- 14.1 Market by Segment
- 14.2 Switzerland
- 14.3 Germany
- 14.4 U.K.
- 14.5 Ireland
- 14.6 Rest of Europe
15. Asia Pacific Biologics CDMO Market, 2021–2035 (USD Billion)
- 15.1 Market by Segment
- 15.2 South Korea
- 15.3 China
- 15.4 Japan
- 15.5 India
- 15.6 Rest of Asia Pacific
16. Latin America Biologics CDMO Market, 2021–2035 (USD Billion)
- 16.1 Market by Segment
- 16.2 Brazil
- 16.3 Mexico
- 16.4 Rest of Latin America
17. Middle East & Africa Biologics CDMO Market, 2021–2035 (USD Billion)
- 17.1 Market by Segment
- 17.2 GCC Countries
- 17.3 South Africa
- 17.4 Rest of Middle East & Africa
18. Competitive Landscape
- 18.1 Market Share Analysis, 2025
- 18.2 Capacity Benchmarking
- 18.3 Mergers, Acquisitions and Partnerships
- 18.4 Capacity Expansions
19. Company Profiles (Overview, Financials, Capacity, Service Portfolio, Strategy, Recent Developments)
- 19.1 Lonza Group
- 19.2 Samsung Biologics
- 19.3 WuXi Biologics
- 19.4 Catalent (Novo Holdings)
- 19.5 Thermo Fisher Scientific
- 19.6 FUJIFILM Biotechnologies
- 19.7 Boehringer Ingelheim BioXcellence
- 19.8 AGC Biologics
- 19.9 Rentschler Biopharma
- 19.10 Charles River Laboratories
- 19.11 Celltrion
- 19.12 National Resilience
20. Appendix
- 20.1 Research Assumptions
- 20.2 Related Reports
- 20.3 About Ameco Research